Decline in Renal Concentration Ability in Lithium Treated Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: M.J. van der Aa
- Phone Number: (073) 553 30 71
- Email: merel.vanderaa@radboudumc.nl
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6532SZ
- Canisius Wilhelmina Ziekenhuis
-
Contact:
- E.M. Bisseling
- Email: e.bisseling@cwz.nl
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- included in the previous study
- men and women
- age ≥ 18 years
Exclusion Criteria:
General contra-indications for participation in a trial:
- inability to give informed consent
- pregnancy
- unstable psychiatric condition
Alternative causes of (nephrogenic) diabetes insipidus:
- hypokalemia (plasma potassium < 3.0 mmol/l)
- severe hypercalcemia (albumin-corrected plasma calcium > 2.80 mmol/l)
- hyperglycemia (plasma glucose > 10.0 mmol/l)
- history of amyloidosis, Sjögren's syndrome or Sickle cell anemia
- previous treatment with ifosfamide
- established primary polydipsia or central diabetes insipidus
Contra-indications for dDAVP administration:
- inability to comply with water restriction
- renal insufficiency (GFR < 45 ml/min/1.73 m2)
- hyponatremia (plasma sodium < 130 mmol/l)
- instable angina pectoris
- decompensated cardial insufficiency
Other:
- concomitant treatment with desmopressin or democlocycline
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
2012-cohort
|
After voiding, 40 μg 1-desamino-8-D arginine vasopressin (dDAVP) will be administered intranasally.
Throughout the day, urine volume and maximal renal concentrating ability will be determined by measuring osmolality in urine collected at 4 and 6 hours after administration of dDAVP.
In addition, water intake, body weight, blood pressure and heart rate will be determined at baseline and 6 hours after administration of dDAVP.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Decline renal concentration ability
Time Frame: 10 years
|
To explore the decline in renal concentration ability (RCA) in a Dutch population of lithium treated patient.
The primary endpoint is the percentual change in maximal urine osmolality.
|
10 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relation between changes in kidney function and renal concentration ability
Time Frame: 10 years
|
To determine the correlation between changes in kidney function and renal concentration ability
|
10 years
|
|
Relation between history of lithium-use and renal concentration ability
Time Frame: 10 years
|
To determine the relationship between renal concentration ability and clinical parameters (duration of lithium therapy, plasma lithium concentration, baseline plasma creatinine, sodium and potassium concentration and baseline urinary osmolality) of lithium treated patients.
|
10 years
|
|
Chronic kidney disease
Time Frame: 10 years
|
To determine the number of patients with chronic kidney disease at follow-up.
|
10 years
|
|
Decline in kidney-function
Time Frame: 10 years
|
To explore the decline in kidneyfunction (expressed as eGFR, estimated by the CKD-EPI equation).
|
10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: T. Nijenhuis, Radboud University Medical Center
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Kidney Diseases
- Urologic Diseases
- Endocrine System Diseases
- Bipolar and Related Disorders
- Pituitary Diseases
- Bipolar Disorder
- Diabetes Insipidus
- Diabetes Insipidus, Nephrogenic
- Physiological Effects of Drugs
- Natriuretic Agents
- Hemostatics
- Coagulants
- Vasoconstrictor Agents
- Antidiuretic Agents
- Vasopressins
- Arginine Vasopressin
- Deamino Arginine Vasopressin
Other Study ID Numbers
Other Study ID Numbers
- NL72701.091.20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.